Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1644 1646 1647 1654 1674
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18379036 | METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 17752407 | ENCODING HIERARCHICAL ASSEMBLY PATHWAYS OF PROTEINS WITH DNA | Non-Final OA | NORTHWESTERN UNIVERSITY |
| 17877814 | COMPOSITIONS COMPRISING EXTRACELLULAR VESICLES, SECRETED BIOMOLECULES, AND/OR CONDITIONED MEDIA, AND METHODS OF PRODUCING AND USING THE SAME | Non-Final OA | L'Oreal |
| 19054646 | METHODS RELATED TO THE TREATMENT OF IGA NEPHROPATHY | Non-Final OA | Ares Trading S.A. |
| 18169497 | COMBINATION THERAPIES FOR TREATMENT OF CANCER WITH THERAPEUTIC BINDING MOLECULES | Final Rejection | MedImmune Limited |
| 17761131 | CD70 TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AND USES THEREOF | Final Rejection | The General Hospital Corporation |
| 18297805 | SOLUBLE TREM2 PROTEIN AND USES THEREOF | Non-Final OA | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18171600 | SOLUBLE CD33 FOR TREATING MYELODYSPLASTIC SYNDROMES (MDS) | Final Rejection | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 17289992 | CYSTEINE ENGINEERED ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | Non-Final OA | Mersana Therapeutics, Inc. |
| 17931868 | SUPPRESSION OF DIABETES USING EXOSOMES FROM STEM CELL PROGRAMMED MYELOID CELLS | Final Rejection | CREATIVE MEDICAL TECHNOLOGIES INC. |
| 17918299 | PEPTIDE FOR THE TREATMENT OF CYTOKINE STORM SYNDROME | Final Rejection | CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA |
| 18299480 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY-ENHANCED SUPPLEMENTATION | Non-Final OA | Xygenyx Inc. |
| 18178783 | COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF | Non-Final OA | MACROGENICS, INC. |
| 18034568 | USE OF REGULATOR OF ITPRIPL1 IN PREPARATION OF DRUG THAT REGULATES IMMUNE RESPONSES OR FIGHTS TUMORS | Non-Final OA | BIOTROY THERAPEUTICS |
| 18040083 | NEUROPILIN AND ANGIOTENSIN CONVERTING ENZYME 2 FUSION PEPTIDES FOR TREATING VIRAL INFECTIONS | Non-Final OA | PINETREE THERAPEUTICS, INC. |
| 18000724 | GROWTH FACTOR COMPOSITION FOR CELL CULTURE-PRODUCED MEAT | Non-Final OA | ORF LIFTAEKNI HF |
| 18047741 | CD24-LOADED VESICLES FOR TREATMENT OF CYTOKINE STORM AND OTHER CONDITIONS | Non-Final OA | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INCORPORATED |
| 17911808 | Use of Anti-IL-6 Antibody, e.g., Clazakizumab for Treatment/Prevention of ARDS Associated with Coronavirus (COVID-19) Infection | Non-Final OA | Vitaeris Inc. |
| 17641378 | ANTI-INFLAMMATORY PEPTIDES, PHARMACEUTICAL COMPOSITION CONTAINING SUCH PEPTIDES, AND USES THEREOF | Non-Final OA | INSTITUTO BUTANTAN |
| 17750444 | PROTEIN PURIFICATION | Final Rejection | UCB PHARMA, S.A. |
| 17414682 | THERAPEUTIC USE OF TRIGONAL GLUCAGON/GLP-1/GIP RECEPTOR AGONIST OR CONJUGATE THEREOF FOR LIVER DISEASE | Final Rejection | HANMl PHARM. CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy